Compare VYGR & AVNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | AVNW |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 204.6M |
| IPO Year | 2015 | 2007 |
| Metric | VYGR | AVNW |
|---|---|---|
| Price | $3.81 | $17.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $16.50 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 511.1K | 240.6K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | $10,135,000.00 | ★ $243,858,000.00 |
| Revenue This Year | $34.04 | $5.59 |
| Revenue Next Year | $7.92 | $7.03 |
| P/E Ratio | ★ N/A | $56.76 |
| Revenue Growth | N/A | ★ 0.56 |
| 52 Week Low | $2.65 | $13.92 |
| 52 Week High | $5.55 | $27.02 |
| Indicator | VYGR | AVNW |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 45.16 |
| Support Level | $3.71 | $14.27 |
| Resistance Level | $4.39 | $22.94 |
| Average True Range (ATR) | 0.27 | 1.04 |
| MACD | -0.03 | 0.16 |
| Stochastic Oscillator | 40.23 | 99.46 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.